BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, the "Research-Use Only" Labelling Test, and What It Means for Legitimate Suppliers
On 1 September 2026, the FDA published five simultaneous warning letters to online peptide sellers, citing the illegal marketing of injectable semaglutide, tirzepatide, retatrutide, tesamorelin and other unapproved compounds. The sweep expands an established enforcement pattern and clarifies how regulators assess "research-use only" claims — with direct implications for compliant research-grade suppliers in the UK and US.
22 Sep 2026
Reputational Risks
Three Texas Recalls in Six Weeks: How Dietary-Grade Glutathione API Triggered a Compounding Safety Crisis — and What State Boards Are Now Saying About Research-Grade Peptides
Three Texas compounding pharmacies recalled injectable glutathione products between August and September 2026 after elevated bacterial endotoxin levels were traced to a shared dietary-supplement-grade API source. With at least 39 adverse events on record, the episode illustrates a recurring quality failure the FDA first warned about in 2019. Separately, Mississippi and South Carolina issued near-identical joint statements in August 2026 barring licensed providers from compounding…
17 Sep 2026
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, One Clear Doctrine on "Research Use Only" Claims
On 1 September 2026, the FDA posted five coordinated warning letters to online peptide vendors — Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC — each cited for marketing unapproved drugs under the guise of research-use-only labelling. The sweep reinforces a doctrine the agency has applied with increasing consistency: website context, bundled reconstitution guides, and dosing calculators can establish human-use intent…
11 Sep 2026
Reputational Risks
Paradigm Peptides Owner Sentenced to 70 Months: What the First Major Criminal Conviction in the Research-Use-Only Market Means for Research Procurement
A US federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison on 30 July 2026, after he admitted importing unapproved drugs from China and India and misrepresenting them as domestically manufactured, FDA-registered products. The case is widely regarded as the first significant criminal prosecution in the largely unregulated "research-use only" peptide marketplace, and it carries direct implications for research procurement officers assessing supplier risk.
31 Aug 2026
Reputational Risks
Compounded GLP-1s and the Additive Problem: What a Tirzepatide-B12 Impurity Study Means for Research Quality Standards
A peer-reviewed study has identified a novel, widespread chemical impurity in mass-compounded tirzepatide products blended with vitamin B12 — a finding that reinforces wider concerns about additive contamination in peptide supply chains and carries direct lessons for research-grade quality assurance.
04 Aug 2026
Reputational Risks
Retatrutide's Illicit Market: What the Surge in Unlicensed "Research Peptide" Sales Means for UK Labs
An investigative report from CBS News published on 8 June 2026, combined with MHRA enforcement raids in the UK and a 265% rise in US poison centre exposures, has brought renewed scrutiny to the grey and black markets for retatrutide. For legitimate research procurement teams, the episode illustrates exactly why the "research-use only" label is under intensifying regulatory pressure on both sides of the Atlantic.
04 Jul 2026
Reputational Risks
MHRA Turns Its Attention to UK Peptide Clinics: What the April 2026 Investigation Means for Legitimate Research Labs
The MHRA has opened investigations into UK clinics making therapeutic claims about unregulated peptide products, following a Guardian exposé and an earlier Criminal Enforcement Unit raid in Lincolnshire. For research-procurement professionals, the enforcement shift clarifies where regulatory tolerance ends — and why robust research-use-only labelling and sourcing discipline matter more than ever.
02 Jun 2026
Reputational Risks
GLP-1 Popularity Is Fuelling Unverified Peptide Promotion Online — and Raising Purity Concerns for Research Procurement
The clinical success of injectable GLP-1 drugs has triggered a surge of social media promotion for a much broader range of unverified peptides, with physicians warning that many products contain minimal active ingredient or outright contaminants. For research-procurement professionals, the same market dynamics create real supply-chain risks that standard vendor screening must address.
19 May 2026